|
IGF-1/ALS Trial Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about IGF-1/ALS Trial conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. IGF-1/ALS Trial Clinical research trials and IGF-1/ALS Trial healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as IGF-1/ALS Trial. IGF-1/ALS Trial Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a IGF-1/ALS Trial clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their IGF-1/ALS Trial condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > IGF-1/ALS Trial  IGF-1/ALS Trial
IGF-1/ALS Trial
For Condition: Amyotrophic Lateral Sclerosis
Status: Recruiting
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.
Details: The objective of this trial is to determine whether IGF-1 (MyotrophinTM) slows progression of weakness in amyotrophic lateral sclerosis (ALS). Three hundred patients with ALS from 16 medical centers will participate in this double blind, placebo-controlled two-year study. Half the patients will receive IGF-1 and the other half will receive placebo. The drug will be administered twice a day. ALS is a neurodegenerative disorder that causes progressive muscle weakness and loss of motor neurons. IGF-1 is a neurotrophic factor essential for normal development of the nervous system and shows protection of motor neurons in animal models and cell culture systems. It is thought to block cell death pathways and promote muscle reinervation and axonal growth and regeneration.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 18 Years/80 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients entering this study: - Are between the ages of 18-80 years old. - Legal residents of the United States or Canada. - Have a history of a chronic onset of a progressive motor weakness of less than 24 months duration. - Fulfill El Escorial criteria of probable or definite ALS. - If female, are surgically sterile, two years postmenopausal, or if of child-bearing potential, must be using a medically acceptable method of birth control and agree to continue use of this method for the duration of the study. Acceptable methods include a barrier method with spermicide, oral contraceptives (normal doses are acceptable; low dose oral contraceptives or contraceptive implants must be used with a barrier method), IUD, or abstinence. Have a negative pregnancy test. - Are able to comply with protocol requirements. - Can provide written informed consent. - Have a manual muscle testing score of less than 8. - Have a forced vital capacity by pulmonary function testing *60% predicted. Exclusion Criteria: Patients entering this study will not: - Have any of the following conditions:renal disease (Creatine > 2.0) or other active systemic disease - Have any clinically significant abnormalities on the prestudy laboratory evaluation, physical examination, ECG, chest x-ray or ophthalmologic exam. - Have any clinically significant medical condition (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure) that, in the opinion of the investigator, would compromise the safety of patient. - Have Type I or Type II diabetes. - Have a history of cancer including melanoma with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline) and carcinoma in-situ of the cervix (women only). - Have used an investigational drug within 30 days of baseline visit. - Have had a tracheostomy. - Have a Beck's Depression Inventory score * 12. - Have legal residency outside of the United States or Canada. - Be pregnant or breast-feeding.
Total Enrollment: 330
Location and Contact Information:
Overall Study Official:
EricSorenson, Principal Investigator, Department of Neurology, Mayo Clinic
Mayo Clinic *Recruiting*
Rochester, Minnesota, 55905
United States
Recruiting Eric Sorenson 507-284-8729
Additional Information:
Study ID Numbers: R01NS42759;
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035815
Other Amyotrophic Lateral Sclerosis Studies:
1. Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
2. Safety testing of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Laughter & Crying)
3. Study evaluating 4 oral doses of TCH346 and placebo administered once daily in patients with Amyotrophic Lateral Sclerosis (ALS)
4. Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis
5. A 12-week, multicenter, safety and dose-ranging study of 3 oral doses of TCH346 in patients with Amyotrophic Lateral Sclerosis
Related Studies:
Other Amyotrophic Lateral Sclerosis Clinical Trials
Other Minnesota Clinical Trials
Other Rochester Clinical Trials
IGF-1/ALS Trial
|
|
|
|
|
|
|
|
